Cover Image
市場調查報告書

CXC趨化素受體類型4 (Fusin/白血球來源、七跨膜區受體、脂多醣相關蛋白質3、基質細胞來源因子1受體、CD184、CXCR4):開發中產品分析

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 ) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 363566
出版日期 內容資訊 英文 100 Pages
訂單完成後即時交付
價格
Back to Top
CXC趨化素受體類型4 (Fusin/白血球來源、七跨膜區受體、脂多醣相關蛋白質3、基質細胞來源因子1受體、CD184、CXCR4):開發中產品分析 C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 ) - Pipeline Review, H2 2017
出版日期: 2017年08月16日 內容資訊: 英文 100 Pages
簡介

本報告提供全球各國的CXC趨化素受體類型4 (別名Fusin/白血球來源、七跨膜區受體,脂多醣相關蛋白質3,為您概述為以下內容基質細胞來源因子1受體,CD184,CXCR4) 治療藥的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

  • 簡介
    • 分析範圍
  • CXC趨化素受體類型4 (Fusin/白血球來源、七跨膜區受體,脂多醣相關蛋白質3,基質細胞來源因子1受體,CD184,CXCR4)的概要
  • 治療藥的開發情形
    • 臨床實驗的各階段
    • 各治療領域
    • 各症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
    • 不明階段的產品
  • 各企業開發中的治療藥
  • 各大學、研究機關開發中的治療藥
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • AdAlta Pty Ltd.
    • Ambrx, Inc.
    • Anchor Therapeutics, Inc.
    • Biokine Therapeutics Ltd.
    • BioLineRx, Ltd.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Globavir Biosciences, Inc.
    • GlycoMimetics, Inc.
    • NeED Pharma s.r.l.
    • Pharis Biotec GmbH
    • Polyphor Ltd.
    • Sanofi
    • TaiGen Biotechnology Co., Ltd.
    • Upsher-Smith Laboratories, Inc.
    • X4 Pharmaceuticals, Inc.
  • 藥物簡介
  • 開發暫停的產品
  • 開發中止的產品
  • 值得注意的最新趨勢、新聞稿
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0962TDB

Title:
C-X-C Chemokine Receptor Type 4
(FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2 2017.

Summary:

According to the recently published report 'C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2017'; C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) pipeline Target constitutes close to 26 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes.

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - C-X-C chemokine receptor type 4 or CD184 is a protein encoded by the CXCR4 gene. It is a receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation, extracellular ubiquitin, leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. It is involved in hematopoiesis and in cardiac ventricular septum formation. It also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells.

The report 'C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2017' outlays comprehensive information on the C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 5, 1, 8 and 1 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Cardiovascular, Immunology, Respiratory, Gastrointestinal, Genetic Disorders, Hematological Disorders, Ophthalmology and Women's Health which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Human Immunodeficiency Virus (HIV) Infections (AIDS), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Breast Cancer, Colon Cancer, Melanoma, Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Small-Cell Lung Cancer, Solid Tumor, Uveal Melanoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Allergic Asthma, Aplastic Anemia, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Glioblastoma Multiforme (GBM), Hematopoietic Stem Cell Transplantation, Idiopathic Pulmonary Fibrosis, Inflammation, Intimal Hyperplasia, Liver Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Myocardial Infarction, Neuroblastoma, Non-Alcoholic Steatohepatitis (NASH), Pancreatic Ductal Adenocarcinoma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Thrombocytopenia, Vasomotor Symptoms of Menopause (Hot Flashes), Waldenstrom Macroglobulinemia, Wet (Neovascular / Exudative) Macular Degeneration, WHIM Syndrome (Warts, Hypogammaglobulinemia and Infections and Myelokathexis).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)
  • The report reviews C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Overview
    • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Companies Involved in Therapeutics Development
    • AdAlta Ltd
    • Ambrx Inc
    • BioLineRx Ltd
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Globavir Biosciences Inc
    • GlycoMimetics Inc
    • Pfizer Inc
    • Pharis Biotec GmbH
    • Polyphor Ltd
    • TaiGen Biotechnology Co Ltd
    • Upsher-Smith Laboratories Inc
    • X4 Pharmaceuticals Inc
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Drug Profiles
    • AD-114 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALB-408 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-3114 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • balixafortide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BL-8040 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • burixafor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GBV-4086 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GMI-1359 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HPH-112 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HPH-196 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HPH-211 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hz-515H7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-2510924 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Antagonize CXCR4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize CXCR4 for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06747143 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • POL-5551 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Protein to Agonize CXCR4 for Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PTX-9908 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Q-122 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Antagonize CXCR4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Target CXCR4 and SDF-1 for HIV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ulocuplumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • USL-311 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • X-4P001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • X-4P002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Dormant Products
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Discontinued Products
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 18, 2017: AD-114 safe in non-human primates and manufacturing progress update
      • Jul 10, 2017: BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer under Immunotherapy Collaboration
      • Jun 01, 2017: BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid Tumors
      • May 25, 2017: X4 Pharmaceuticals Announces Initiation of the Phase 2 Expansion of its Phase 1/2 Study of X4P-001 in Patients with Advanced Clear Cell Renal Cell Carcinoma
      • May 22, 2017: BioLineRx Announces Regulatory Submission for Phase 1b Trial of BL-8040 in Combination with Atezolizumab in AML
      • May 08, 2017: AdAlta to present eye fibrosis data at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
      • May 03, 2017: BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA
      • Mar 21, 2017: AdAlta expands collaboration with The Alfred Hospital
      • Mar 20, 2017: BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment
      • Mar 02, 2017: GlycoMimetics to Present New Preclinical Data of GMI-1359 at AACR Annual Meeting 2017
      • Jan 30, 2017: X4 Pharmaceuticals Announces Initiation of a Phase 2/3 Clinical Study of X4P-001-LD in Patients with WHIM Syndrome, a Rare Genetic Primary Immunodeficiency Disease
      • Jan 26, 2017: X4 Pharmaceuticals Announces Initiation of Clinical Study of X4P-001 in Combination with Opdivo for Patients with Advanced Clear Cell Renal Cell
      • Jan 18, 2017: AdAlta receives Orphan Designation for its lead drug candidate targeting patients with idiopathic pulmonary disease
      • Jan 17, 2017: BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA for Pancreatic Cancer
      • Jan 09, 2017: AdAlta Announces Positive Pre-clinical Data Showing Lead Drug Candidate Has Broad Fibrosis Treatment Potential
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by AdAlta Ltd, H2 2017
  • Pipeline by Ambrx Inc, H2 2017
  • Pipeline by BioLineRx Ltd, H2 2017
  • Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Pipeline by Eli Lilly and Company, H2 2017
  • Pipeline by Globavir Biosciences Inc, H2 2017
  • Pipeline by GlycoMimetics Inc, H2 2017
  • Pipeline by Pfizer Inc, H2 2017
  • Pipeline by Pharis Biotec GmbH, H2 2017
  • Pipeline by Polyphor Ltd, H2 2017
  • Pipeline by TaiGen Biotechnology Co Ltd, H2 2017
  • Pipeline by Upsher-Smith Laboratories Inc, H2 2017
  • Pipeline by X4 Pharmaceuticals Inc, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017
  • Dormant Products, H2 2017 (Contd..3), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top